



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/796,902

03/09/2004

Jun Li

11287.105001 AST100

1631

20786 7590 03/17/2008

KING & SPALDING LLP
1180 PEACHTREE STREET
ATLANTA, GA 30309-3521

EXAMINER

FUBARA, BLESSING M

ART UNIT

PAPER NUMBER

1618

MAIL DATE

DELIVERY MODE

03/17/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/796,902	Applicant(s) LI ET AL.	
	Examiner BLESSING M. FUBARA	Art Unit 1618	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 08 October 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-24 is/are pending in the application.
- 4a) Of the above claim(s) 19,20,23 and 24 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-18, 21 and 22 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Examiner acknowledges receipt of response restriction requirement filed 10/08/07.

Claims 1-24 are pending.

Election/Restrictions

1. Applicant's election without traverse of Group I, claims 1-18 and 21-24 in the reply filed on 10/08/07 is acknowledged. Applicant also elected liver assist device. Claim 20 was inadvertently included in Group I in the office action of 9/06/07. A correction is thus made and that is reflected in the claims under consideration. Thus claims 1-18, 21 and 22 are examined.

Claim Rejections - 35 USC § 112

2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

3. Claim 22 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

4. Claim 22 provide for the use of the microcapsules of claim 1, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

Claim 22 is rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex*

Art Unit: 1618

parte Dunki, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd. v. Brenner*, 255 F.

Supp. 131, 149 USPQ 475 (D.D.C. 1966).

Claim Rejections - 35 USC § 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

6. Claims 1, 2, 10-13, 17, 18 and 21 are rejected under 35 U.S.C. 102(b) as being anticipated by Fick (US 5,945,100) or Lu et al. ("Cell Encapsulation with Alginate and ω -Phenoxycinnamylidene-Acetylated Poly(allylamine," in *Biotechnol. Bioeng.*, 2000, 70 (5), pp. 479-483).

7. Fick discloses tumor delivery vehicle that can be made of natural polymers (column 8), synthetic polymers that are cross-linkable by hydrogen bonding (column 10, line 45 to column 11, line 10); Fick contemplates the use of water soluble polymers that include cinnamoyl groups that may be photochemically cross-linked (column 11, lines 22-25). These polymers are used for encapsulating bioactive agents with the polymers forming semipermeable membrane around the encapsulated materials (column 12, lines 64, 65; column 8, lines 51-54). Fick meets the requirements of the claims in terms of microcapsule, semipermeable membrane, the presence of cinnamoyl groups on the membrane and in terms of the bioactive agent .

8. Lu discloses microcapsules that comprise semipermeable polymer membrane that is used to encapsulate cells; the polymer comprises alginate and two types of photosensitive polyallylamine that are modified by α -phenoxycinnamylidene acetyl chloride (abstract). Lu

Art Unit: 1618

thus meets the requirement of the claims in times of the semipermeable microcapsule, cells as bioactive agents, and the presence of cinnamoyl groups in the membrane.

Claim Rejections - 35 USC § 103

9. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

10. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

11. Claims 1-18, 21 and 22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lu et al. ("Cell Encapsulation with Alginate and ω -Phenoxycinnamylidene-Acetylated Poly(allylamine)," in *Biotechnol. Bioeng.*, 2000, 70 (5), pp. 479-483) in view of Chia et al. ("Hepatocyte Encapsulation for enhanced Cellular Functions," in *Tissue Engineering*, Vol. 6, no. 5, (2000) pp. 481-495) or Sun et al. ("Microencapsulated Hepatocytes: AN in Vitro and in vivo study," *Biomater. Artif. Cells Art. Org.*, 1987, 15, pp 1483-1496).

Claims 1, 2, 10-13, 17 and 18 have been shown above to be anticipated by Lu. Lu teaches microparticles that is comprised of polymer and would flow that that microcapsules have

Art Unit: 1618

inner and outer layer that are made up of polymer; claim 3 does not distinguish the first and second polymers, and Lu teaches two types of polymers and thus meets claim 3. The electrical charge on the polymer of the microcapsule of claim 4 would be inherent to the microcapsule of Lu. Claims 57 are met because the membrane of Lu has cinnamoyl groups. Regarding claims 8 and 9, the specific polymers used can be used in the Lu delivery vehicles. Regarding claim 16, one cinnamoyl compound can be used in place of the other. For claim 14, the artisan has the technical expertise to determine how much cinnamoyl compound can be used to obtain the desired concentration of cinnamoyl groups on the membrane and for claim 15, the specification does not provide unexpected result deriving from the particle size. Claim 18 is a combination of claims 1, 17, 3 and 4 so that claim 18 is inherent and in the absence of factual evidence of unexpected result, the particle size does not patentably distinguish the invention over the prior art. Exposing the cinnamoyl to light at a particular wavelength of 340 nm to 700 nm, which is in the visible region of the spectrum, is a process of carrying out the cross-linking and thus makes claim 18 a product by process claim. Lu does not disclose the use of the delivery vehicle in a liver assist device. But both Chia and Sun disclose the use of alginate-polyamino acid membrane for encapsulating hepatic cells. Therefore, taking the general teachings of Lu as encapsulating cells, one having ordinary skill in the art at the time the invention was made would have reasonable expectation of success that the device of LU would effectively encapsulate cells including liver cells.

No claim is allowed.

Art Unit: 1618

Any inquiry concerning this communication or earlier communications from the examiner should be directed to BLESSING M. FUBARA whose telephone number is (571)272-0594. The examiner can normally be reached on 7 a.m. to 5:30 p.m. (Monday to Thursday).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Blessing M. Fubara/
Examiner, Art Unit 1618